Impact Biomedical (IBO) insider amends holdings after May share sales

Rhea-AI Filing Summary

Impact Biomedical Inc. reported insider share sales by a reporting entity that is a wholly owned subsidiary of DSS, Inc. The insider sold 115,600 shares of common stock on 05/22/2025 at an average price of $0.5491 per share and 45,400 shares on 05/27/2025 at an average price of $0.5403 per share, both coded as sales. After these transactions, the reporting person beneficially owns 545,024 shares of Impact Biomedical common stock, held directly.

The filing is an amendment that corrects a previous error in the number of Impact Biomedical shares that DSS, Inc. beneficially owns. The corrected figure includes 545,024 shares received in connection with the Celios asset sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DSS, INC.

(Last) (First) (Middle)

275 WIREGRASS PKWY

(Street)

HENRIETTA NY 14586

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IMPACT BIOMEDICAL INC. [ IBO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2025		S		115,600	D	$0.5491	590,424	D
Common Stock	05/27/2025		S		45,400	D	$0.5403	545,024	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This entity is a wholly-owned subsidiary of DSS, Inc. This amendment filing corrects an error in connection with the number of total shares of Common Stock that DSS, Inc. beneficially owns of IBO from its previously filed Form 4 on May 27, 2025. This corrected amendment includes DSS' correct beneficial ownership of IBO, which includes 545,024 shares of IBO's common stock pursuant to the Celios Asset sale.

	/s/ Jason Grady	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity was reported for Impact Biomedical (IBO)?

The reporting entity, a wholly owned subsidiary of DSS, Inc., reported two open-market sales of Impact Biomedical common stock on 05/22/2025 and 05/27/2025, both coded as sales ("S").

How many Impact Biomedical (IBO) shares were sold and at what prices?

The insider sold 115,600 shares of Impact Biomedical common stock on 05/22/2025 at an average price of $0.5491 per share and 45,400 shares on 05/27/2025 at an average price of $0.5403 per share.

How many Impact Biomedical (IBO) shares does the insider own after these transactions?

Following the reported transactions, the reporting person beneficially owns 545,024 shares of Impact Biomedical common stock in direct ownership form.

Why is this Impact Biomedical (IBO) Form 4 labeled as an amendment?

This Form 4 is an amendment to correct an error in the previously reported total number of Impact Biomedical common shares beneficially owned by DSS, Inc. as of the earlier filing on May 27, 2025.

What is the connection between DSS, Inc. and Impact Biomedical (IBO) in this filing?

The reporting person in this filing is described as a wholly-owned subsidiary of DSS, Inc., and the amendment clarifies DSS, Inc.'s correct beneficial ownership in Impact Biomedical common stock.

What role does the Celios asset sale play in the reported IBO share ownership?

The corrected beneficial ownership includes 545,024 Impact Biomedical common shares that are attributed to DSS, Inc. pursuant to the Celios asset sale.

Is the reporting person a director or officer of Impact Biomedical (IBO)?

The form identifies the reporting person’s relationship to Impact Biomedical as a Director, with no officer title specified in the excerpt.